Gemzar for Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

INDIANAPOLIS--Eli Lilly and Company's Gemzar (gemcitabine) is now available for use in the treatment of advanced pancreatic cancer.

INDIANAPOLIS--Eli Lilly and Company's Gemzar (gemcitabine) isnow available for use in the treatment of advanced pancreaticcancer.

"As the first new treatment for pancreatic cancer in severaldecades, Gemzar represents hope for patients and a breakthroughfor Lilly scientists," said August M. Watanabe, MD, executivevice president of the company.

Gemzar, a nucleoside analog, is the first chemotherapy agent toreceive FDA clearance based on a unique clinical endpoint--clinicalbenefit response--designed to objectively assess the effect ofthe drug on measured disease-related symptoms. In two clinicaltrials, about one quarter of patients treated with Gemzar demonstratedimprovement in symptoms.

Gemzar is indicated as first-line treatment for patients withlocally advanced (nonresectable stage II or III) or metastatic(stage IV) adenocarcinoma of the pancreas, and is also indicatedfor patients previously treated with fluorouracil.

Recent Videos
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Related Content